| Literature DB >> 20518060 |
Abstract
Type I interferons (IFN) are cytokines with many functions and have been widely used to treat many human diseases such as hepatitis C virus infection. Using the viral transformation and priming properties of Epstein-Barr virus, we have developed a system that can produce high levels of "personalized" IFNs, which are produced from the cells of the patient to whom the IFNs are to be administrated. We demonstrate the feasibility of the system. This seems to be the first report for the establishment of a personalized IFN-production system. The personalized IFNs could have a longer circulation time, fewer side effects but higher efficacy. We anticipate that the system can provide an improved form of IFN for medical uses.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20518060 PMCID: PMC3023146 DOI: 10.1002/biot.201000038
Source DB: PubMed Journal: Biotechnol J ISSN: 1860-6768 Impact factor: 4.677